Axon Enterprise, Inc. (NASDAQ:AXON) Position Decreased by Rhumbline Advisers

Rhumbline Advisers decreased its holdings in shares of Axon Enterprise, Inc. (NASDAQ:AXON) by 2.4% in the 4th quarter, HoldingsChannel.com reports. The firm owned 146,359 shares of the biotechnology company’s stock after selling 3,525 shares during the period. Rhumbline Advisers’ holdings in Axon Enterprise were worth $86,984,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the business. Asset Dedication LLC boosted its holdings in shares of Axon Enterprise by 11.3% in the fourth quarter. Asset Dedication LLC now owns 178 shares of the biotechnology company’s stock worth $106,000 after buying an additional 18 shares during the period. Bleakley Financial Group LLC boosted its holdings in shares of Axon Enterprise by 1.3% in the fourth quarter. Bleakley Financial Group LLC now owns 1,527 shares of the biotechnology company’s stock worth $908,000 after buying an additional 20 shares during the period. Insigneo Advisory Services LLC boosted its holdings in shares of Axon Enterprise by 1.4% in the third quarter. Insigneo Advisory Services LLC now owns 1,568 shares of the biotechnology company’s stock worth $627,000 after buying an additional 22 shares during the period. Menard Financial Group LLC boosted its holdings in shares of Axon Enterprise by 0.8% in the third quarter. Menard Financial Group LLC now owns 3,014 shares of the biotechnology company’s stock worth $1,204,000 after buying an additional 24 shares during the period. Finally, PFG Investments LLC boosted its holdings in shares of Axon Enterprise by 0.6% in the third quarter. PFG Investments LLC now owns 3,872 shares of the biotechnology company’s stock worth $1,547,000 after buying an additional 25 shares during the period. Institutional investors own 79.08% of the company’s stock.

Insider Activity at Axon Enterprise

In related news, Director Julie A. Cullivan sold 1,261 shares of the firm’s stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $682.06, for a total transaction of $860,077.66. Following the transaction, the director now owns 2,392 shares of the company’s stock, valued at approximately $1,631,487.52. This trade represents a 34.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michael Garnreiter sold 1,000 shares of the firm’s stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $639.69, for a total transaction of $639,690.00. Following the transaction, the director now directly owns 24,259 shares in the company, valued at approximately $15,518,239.71. The trade was a 3.96 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 8,711 shares of company stock valued at $5,631,561. 6.10% of the stock is currently owned by corporate insiders.

Axon Enterprise Price Performance

Shares of AXON opened at $683.41 on Friday. The firm has a market cap of $52.11 billion, a PE ratio of 176.59, a PEG ratio of 6.79 and a beta of 1.05. The firm’s 50 day moving average price is $623.22 and its 200 day moving average price is $507.71. The company has a debt-to-equity ratio of 0.32, a quick ratio of 2.63 and a current ratio of 2.96. Axon Enterprise, Inc. has a twelve month low of $260.27 and a twelve month high of $698.67.

Analysts Set New Price Targets

AXON has been the subject of several recent analyst reports. Morgan Stanley upgraded shares of Axon Enterprise from an “equal weight” rating to an “overweight” rating and raised their target price for the stock from $500.00 to $700.00 in a report on Tuesday, December 3rd. Northland Securities raised their target price on shares of Axon Enterprise from $365.00 to $550.00 and gave the stock an “outperform” rating in a report on Monday, November 11th. The Goldman Sachs Group increased their price target on shares of Axon Enterprise from $500.00 to $700.00 and gave the stock a “buy” rating in a research report on Monday, January 27th. JMP Securities increased their price target on shares of Axon Enterprise from $610.00 to $725.00 and gave the stock a “market outperform” rating in a research report on Tuesday, February 4th. Finally, Robert W. Baird increased their price target on shares of Axon Enterprise from $600.00 to $800.00 and gave the stock an “outperform” rating in a research report on Friday, December 6th. One analyst has rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $542.15.

Axon Enterprise Company Profile

Axon Enterprise, Inc develops, manufactures, and sells conducted energy devices (CEDs) under the TASER brand in the United States and internationally. It operates through two segments, Software and Sensors, and TASER. The company also offers hardware and cloud-based software solutions that enable law enforcement to capture, securely store, manage, share, and analyze video and other digital evidence.